Edition:
United States

Bristol-Myers Squibb Co (BMYMP.PK)

BMYMP.PK on OTC Markets Group

985.00USD
11:49am EDT
Change (% chg)

$45.00 (+4.79%)
Prev Close
$940.00
Open
$985.00
Day's High
$985.00
Day's Low
$985.00
Volume
4
Avg. Vol
23
52-wk High
$1,231.90
52-wk Low
$788.70

BMYMP.PK

Chart for BMYMP.PK

About

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small... (more)

Overall

Beta: 1.08
Market Cap(Mil.): $88,586.09
Shares Outstanding(Mil.): 1,647.50
Dividend: 0.39
Yield (%): 2.90

Financials

  BMYMP.PK Industry Sector
P/E (TTM): 20.24 29.39 30.30
EPS (TTM): 2.66 -- --
ROI: 18.67 13.71 13.24
ROE: 29.28 14.66 14.40

BRIEF-Bristol-Myers CFO: potential for 2017 U.S. growth for Opdivo

* Cfo says now believes "there is potential for Opdivo to grow in the U.S. this year," even with increased competition

11:48am EDT

Bristol-Myers beats Wall St estimates, helped by cancer drug Opdivo

NEW YORK Bristol-Myers Squibb Co on Thursday reported higher-than-expected quarterly earnings, helped by increased sales of cancer drugs Opdivo and Yervoy and blood thinner Eliquis.

10:35am EDT

UPDATE 1-Bristol-Myers beats Wall St estimates, helped by cancer drug Opdivo

NEW YORK, April 27 Bristol-Myers Squibb Co on Thursday reported higher-than-expected quarterly earnings, helped by increased sales of cancer drugs Opdivo and Yervoy and blood thinner Eliquis.

10:34am EDT

BRIEF-Bristol-Myers Squibb posts Q1 earnings per share of $0.94

* Q1 earnings per share $0.94; Q1 adjusted earnings per share $0.84; Q1 revenues $4.93 billion, up 12 percent

7:13am EDT

Bristol-Myers beats Wall St estimates, helped by Cancer drug Opdivo

NEW YORK, April 27 Bristol-Myers Squibb Co on Thursday posted better-than-expected first-quarter earnings, helped by growth from cancer drugs Opdivo and Yervoy and blood thinner Eliquis.

6:59am EDT

U.S. Supreme Court may limit where companies can be sued

WASHINGTON, April 25 U.S. Supreme Court justices on Tuesday signaled a willingness to place limits on where corporations can be sued in a dispute involving drug maker Bristol-Myers Squibb Co, a potential setback to plaintiffs' lawyers who try to bring suits in friendly courts.

Apr 25 2017

BRIEF-Transgene and Bristol-Myers Squibb announce clinical research collaboration

* Co and Bristol-Myers Squibb announce clinical research collaboration to evaluate TG4010 with Opdivo and Standard Chemotherapy in First Line Non-Small Cell Lung Cancer

Apr 25 2017

Bristol-Myers NASH drug reduces liver fat in midstage study

Bristol-Myers Squibb Co said its lead experimental drug for nonalcoholic steatohepatitis, or NASH, significantly reduced liver fat versus placebo, according to data from a mid-stage trial presented at a medical meeting on Saturday.

Apr 22 2017

Bristol-Myers NASH drug reduces liver fat in midstage study

April 22 Bristol-Myers Squibb Co said its lead experimental drug for nonalcoholic steatohepatitis, or NASH, significantly reduced liver fat versus placebo, according to data from a mid-stage trial presented at a medical meeting on Saturday.

Apr 22 2017

BRIEF-Bristol-Myers gets positive CHMP opinion recommending approval of Opdivo for treatment of a type of bladder cancer

* Bristol-Myers Squibb receives positive CHMP opinion recommending approval of Opdivo (Nivolumab) for the treatment of patients with previously treated locally advanced or metastatic urothelial carcinoma, a type of bladder cancer

Apr 21 2017

More From Around the Web

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $124.16 +0.65
Pfizer Inc. (PFE.N) $33.99 +0.14
Merck & Co., Inc. (MRK.N) $62.77 +0.07
Sanofi SA (SASY.PA) €85.97 +0.32
AstraZeneca plc (AZN.L) 4,698.00 +11.50
GlaxoSmithKline plc (GSK.L) 1,558.50 -7.50
Eli Lilly and Co (LLY.N) $81.51 +0.55
Roche Holding Ltd. (ROG.S) CHF260.30 +2.50
Roche Holding Ltd. (RO.S) CHF261.50 +3.00

Earnings vs. Estimates